Epiruba 2 mg/ml (IV Infusion)

10 mg vial: ৳ 900.00

Medicine Details

Category Details
Generic Epirubicin hydrochloride
Company Drug international ltd

Title

  • Epiruba Injection

Categories

  • Cytotoxic Chemotherapy

Description

  • Indications as adjuvant therapy in breast cancer patients with axillary node tumor involvement
  • Pharmacological action via inhibiting DNA and RNA synthesis
  • Dosage administered by intravenous infusion in repeated 3-to 4-week cycles
  • Interaction with cardioactive compounds and other cytotoxic drugs
  • Contraindications for patients with hypersensitivity to Epirubicin
  • Reported side effects including myelosuppression and cardiotoxicity
  • Pregnancy Category D, with potential risk to the fetus
  • Precautions for handling and disposal, administration only under qualified supervision
  • Pediatric uses including dosage adjustments and bone marrow dysfunction considerations
  • Storage conditions at 2-8°C, protection from light and children

Dimensions

    Color Options

      Functions

      • Inhibits DNA and RNA synthesis
      • Rapid and wide distribution into tissues upon IV administration
      • Extensively metabolized by the liver
      • Elimination through biliary and urinary excretion
      • Patient recovery from acute toxicities before treatment
      • Supportive care for potential myelosuppression and cardiotoxicity
      • Dosage adjustments based on hematologic and non-hematologic toxicities
      • Administration considerations for patients with hepatic and renal impairment

      Materials

        Technical Specifications

        • Total dose of 100 to 120 mg/m² recommended for Epirubicin
        • Dosage regimens - CEF-120, FEC-100
        • Close monitoring of cardiac function during treatment with cardioactive compounds
        • Excretion through biliary and urinary pathways
        • Terminal elimination half-life of 30-40 hrs
        • Epiruba Day 1 dose reduction in subsequent cycles for certain toxicities
        • Storage at 2-8°C to avoid gelled product formation

        Design Elements

          Usability Features

          • Careful baseline assessment of blood counts, serum levels, and cardiac function before treatment
          • Administration under supervision of qualified physicians experienced in cytotoxic therapy
          • Recommendations for drug handling and preparation
          • Observation over time for signs of CHF in case of overdose

          Related Brands